Trastuzumab emtansine for treating unresectable metastatic HER2-positive breast cancer after treatment with trastuzumab and a taxane
Status Complete
Process STA
Topic area
  • Cancer


Key events during the development of the guidance:

Date Update
22 December 2015 Invitation to participate
16 December 2015 Expected publication
16 December 2015 Guidance published
17 November 2015 - 01 December 2015 Final appraisal determination
Dates Notes
02 July 2015

Following the appeal against the Final Appraisal Determination (FAD) for this appraisal, NICE has developed a position statement on the relevance of the 'PPRS Payment Mechanism' of the Pharmaceutical Price Regulation Scheme (PPRS) 2014 to the assessment of the cost effectiveness of branded medicines.

The Committee will meet on 29th September 2015 to discuss the outcome of the appeal and to reconsider the relevance of the PPRS in the light of the position statement. Consultees and commentators have been invited to give their views on the relevance of the PPRS and the position statement in relation to this appraisal.

23 May 2014

The Committee discussion for trastuzumab emtansine for treating HER2-positive, locally advanced or metastatic breast cancer that was due to take place on 28 May 2014 has been cancelled. This is due to the consideration of a commercial arrangement proposed by the manufacturer.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance